The binding sites of three typical calcium channel antagonists, 1,4-dihydropyridines, benzothiazepines and phenylalkylamines, were successfully identified within the primary structures of calcium channels using a photoaffinity labeling technique. The results confirm pharmacological observations of the three antagonists that had been proposed to interact allosterically with each other. We briefly review the results and discuss the future prospects. (Jpn Heart J 1996; 37: 643-650) 
-TYPE calcium channels are complex oligometric membrane proteins that regulate voltage-dependent influx of calcium into excitable cells.1) They represent one of the key components of the excitation-contraction coupling machinery in the muscle cells.2) They are also the receptors for drugs called calcium antagonists or calcium channel blockers.3) These drugs play an important role in the treatment of many different cardiovascular disorders, particularly hypertension and angina pectoris.4) Among a number of compounds which act as calcium channel blockers, 1,4-dihydropyridines (DHP), phenylalkylamines (PAA) and benzothiazepines (BTZ) are three typical classes of calcium antagonists. All three classes of calcium antagonists, in spite of their different chemical structures, which include heterocycles (Figure 1 ), specifically bind to the a, subunit of the Ltype calcium channel and prevent calcium influx into the cells. Binding studies using radioisotope-labeled drugs suggest that the binding sites of the three drugs are different but they interact allosterically with each other,5) as shown in Figure  2 .
Progress in ion channel studies in the past decade, owing largely to molecular biological techniques, have made it possible to elucidate the primary structures of ion channels; the sodium channel from electric eels was the first ex- Figure 4 . DHP binds the extracellular site composed of the IIIS5-IIIS6 loop and the extracellular mouth of IVS6, and BTZ binds another extracellular site, part of which is composed of the IVS5-IVS6 loop. By contrast, PA binds the intracellular site which consists of the intracellular mouth of IVS6. These findings not only explain the pharmacological allosteric binding of the three calcium antagonists (Figure 2 ) in more detail on the basis of the calcium channel structure, but also shed light on the molecular entity of extracellular and intracellular constituents of the channel pore to which the calcium antagonists bind and block the calcium ion permeation.
In addition, the chemically identified sites for the three antagonists are highly conserved in amino acid sequences among L-type calcium channels from skeletal muscle, heart and neurons. This finding may provide ideas with which to modify or create new calcium antagonists with different pharmacological characteristics. Minor modifications of these basic drug structures, for example, might yield similarly selective, efficient antagonists of other calcium channel subtypes. Computer-assisted drug designs have been advanced recently. The designs are greatly assisted by three-dimensional structural information on drug receptors. In this respect, three-dimensional elucidation of the calcium channel, and the channel-drug complex in particular, is being eagerly awaited.
